Tonix Pharmaceuticals Holding Corp (NAS:TNXP)
$ 0.1755 0.001 (0.57%) Market Cap: 16.77 Mil Enterprise Value: 19.54 Mil PE Ratio: 0 PB Ratio: 0.12 GF Score: 34/100

Tonix Pharmaceuticals discusses exclusive license of potential monoclonal antibodies Transcript

Feb 01, 2023 / NTS GMT
Release Date Price: $7.31 (+4.46%)
Natalie Stoberman
Proactive Investors - Analyst

Welcome to the Proactive studios. I'm Natalie Stoberman, joined by the CEO of Tonix Pharmaceuticals, Seth Lederman. Seth, how are you doing today?

Seth Lederman
Tonix Pharmaceuticals Holding Corp. - Co-Founder, CEO & Chairman

Thank you. Well, thanks for having me on.

Questions & Answers

Natalie Stoberman
Proactive Investors - Analyst

Of course. It's a pleasure to have you on. And there are big news coming out of the company, but we're zoning in on something that has been around for a few months now, but because it's progressing and related to COVID-19, things change quickly. So with the new licensing agreement with Curia Global for monoclonal antibody treatment, where are we at with that agreement that came out in December?

Seth Lederman
Tonix Pharmaceuticals Holding Corp. - Co-Founder, CEO & Chairman

Thank you, Natalie. We're excited about licensing these three monoclonal antibodies from Curia because

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot